Breaking the Curse: How Remibrutinib's MS Win Could Rewrite the BTK Inhibitor Story

For years, the BTK inhibitor class carried a promise it could not quite keep in multiple sclerosis. The biology was compelling: Bruton's tyrosine kinase sits at a critical junction in B cell and innate immune cell signaling, and blocking it offered a way to suppress the neuroinflammation that drives relapsing MS through a mechanism distinct from anything already on the market. The problem was the liver. One after another, BTK inhibitors entering MS trials generated hepatotoxicity signals that stopped programs in their tracks, triggered FDA clinical holds, and ultimately cost Sanofi a regulatory approval. The class became defined as much by what it could not safely do as by what it might achieve.

On September 1, 2026, Novartis announced that remibrutinib, its highly selective oral BTK inhibitor already approved as Rhapsido for chronic spontaneous urticaria, had met the primary endpoint in both the REMODEL-1 and REMODEL-2 Phase 3 trials in adults with relapsing multiple sclerosis. The drug demonstrated statistically significant superiority over teriflunomide in reducing annualized relapse rate, hit all key secondary endpoints including reductions in MRI lesions, and showed clinically meaningful trends in disability progression. And it did all of this with no liver safety signal. No cases meeting Hy's Law criteria. No hepatotoxicity flags across nearly 2,000 patients enrolled in the two identical trials.

That last detail is not a footnote. It is the story.

What Went Wrong Before, and Why It Matters Now

The history of BTK inhibitors in MS is a cautionary tale about the gap between mechanism and molecule. Sanofi's tolebrutinib generated genuine excitement before liver enzyme elevations accumulated in its trials, including six cases meeting Hy's Law criteria. The FDA issued a complete response letter citing severe drug-induced liver injury risk, and the program that had once been positioned as a potential blockbuster in progressive MS ended without an approval. Roche's fenebrutinib encountered a partial clinical hold in 2023 following two cases of elevated liver enzymes, and its Phase 3 FENhance trials subsequently recorded one Hy's Law case for the drug and one for the comparator, alongside a death imbalance that drew scrutiny. The pattern was consistent enough that the liver had become the defining obstacle for the entire class in MS.

Remibrutinib's clean hepatic profile across more than 4,500 clinical trial participants in multiple indications, including the REMODEL trials, suggests the toxicity was not a class effect but a molecule-specific one. The drug's high selectivity for BTK, which Novartis has emphasized since its early development, appears to translate into a meaningfully different safety profile than the less selective inhibitors that preceded it. Whether that distinction holds up across broader post-approval populations will take time to establish, but the Phase 3 data are the most rigorous test available, and they are unambiguous on this point.

What the REMODEL Data Actually Show

The REMODEL-1 and REMODEL-2 trials enrolled approximately 2,000 patients globally with relapsing MS and an Expanded Disability Status Scale score between 0.0 and 5.5, randomized 1:1 to receive remibrutinib 100 mg or teriflunomide. Teriflunomide is a well-established oral therapy for relapsing MS, making it a meaningful comparator rather than a low bar. The primary endpoint of annualized relapse rate was met with statistical significance in both trials independently, a design choice that strengthens the evidentiary case considerably compared to programs that rely on a single pivotal study.

The secondary endpoint picture adds important nuance. Both trials showed superiority on MRI measures of inflammatory disease activity, including new or enlarging T2 lesions and gadolinium-enhancing T1 lesions. On disability progression, the preplanned combined analysis of REMODEL-1 and REMODEL-2 showed a positive trend in three-month confirmed disability progression and nominal statistical significance at six months. Novartis CEO Vas Narasimhan had previously defined a mid-teens improvement in disability progression as clinically meaningful, and the combined analysis appears to approach that threshold. The full data will be presented at MSToronto2026 in October, where the detailed numbers will allow the field to assess exactly where remibrutinib sits relative to the high-efficacy therapies that currently define the top of the MS treatment hierarchy.

Where Remibrutinib Fits in a Crowded Market

The MS treatment landscape is not short of options. Roche's Ocrevus, an infused anti-CD20 antibody, has been the dominant high-efficacy therapy for years. Novartis's own Kesimpta, a self-injected anti-CD20 agent, has been growing rapidly as a more convenient alternative. The question for remibrutinib is not whether it can beat teriflunomide, which it has now demonstrated, but whether it can carve out a meaningful position relative to the B cell-depleting biologics that have become the standard of care for patients with active disease.

The answer may lie in the mechanism itself. Anti-CD20 therapies deplete B cells broadly and durably, which produces strong efficacy but also raises long-term questions about immunosuppression, infection risk, and the management of patients who want to start families. Remibrutinib, as a BTK inhibitor, modulates B cell and innate immune cell signaling without depleting the cells entirely. That distinction could matter for specific patient populations, including younger patients, those with infection concerns, or those who prefer an oral therapy over an infusion or injection. Novartis has framed remibrutinib as a potential option to be given ahead of biologics, positioning it as a high-efficacy oral alternative rather than a last resort.

The Broader Implications for the BTK Class

The REMODEL results arrive at a moment when the BTK inhibitor story in MS had largely been written off. Sanofi's rejection, Roche's safety complications, and the general perception that the class could not clear the liver toxicity hurdle had dampened enthusiasm for the mechanism. Remibrutinib's clean Phase 3 data reopen that conversation in a meaningful way.

For Novartis, the timing carries additional significance. The company has faced a concentrated period of clinical setbacks in 2026, including the failure of del-desiran in myotonic dystrophy type 1, the pelacarsen cardiovascular miss, and the pause of its autoimmune CAR-T program following patient deaths. The REMODEL win does not erase those setbacks, but it demonstrates that the company's neuroscience pipeline retains genuine depth. Remibrutinib is also being studied in secondary progressive MS through the REMASTER trial, and in other immune-mediated conditions including hidradenitis suppurativa and food allergy. A successful regulatory submission in relapsing MS would establish the drug as a multi-indication platform asset rather than a single-indication product.

What Comes Next

Novartis has said it plans to seek regulatory approval for remibrutinib in relapsing MS globally, with the detailed REMODEL data to be presented at MSToronto2026 in October. The regulatory pathway in MS is well established, and a drug that has beaten an active comparator in two identical Phase 3 trials with a clean safety profile is in a strong position for submission. The timeline to approval will depend on how quickly Novartis can compile and submit the full data package, but the topline results provide the foundation that regulators will need to evaluate.

For the nearly three million people worldwide living with multiple sclerosis, the arrival of a high-efficacy oral option with a differentiated safety profile would represent a genuine addition to the treatment toolkit. The BTK inhibitor class spent years promising something it could not safely deliver. The REMODEL data suggest that promise may finally be within reach.